Home Microbial Fermentation Services pAVEway™ Microbial Expression Platform

pAVEway™ Microbial Expression Platform

pAVEway™ is an efficient microbial protein expression and scale-up platform

pAVEway™ is a proven and innovative technology platform for the efficient microbial expression of proteins based on E.coli. The system offers industry-leading titers with proven scalability in more than one hundred projects over the last decade. Time to first clinical manufacture and strain generation has been reduced from six to four weeks, through ambr 250 technology.

Antibiotic-free fermentation ensures low regulatory risk without the loss of yield or versatility. And the class leading fermentation productivity ensures high yield recombinant protein production for a wide range of targets.

pAVEway™ offers efficient expression for a wide range of biotherapeutic proteins, through a variety of accumulation routes; intracellular soluble, intracellular insoluble, and periplasmic secretion. The optimal route can be tailored for each individual protein.

pAVEway™ offers efficient expression for a wide range of biotherapeutic proteins, through a variety of accumulation routes; intracellular soluble, intracellular insoluble, and periplasmic secretion. The optimal route can be tailored for each individual protein.

Image of ambrTM 250 technology

BENIFITS

Industry leading titers

  • High producing E.coli strains selected Highly efficient expression of recombinant proteins Robust fermentation performance at high cell densities.

Speed

  • Fast track process creation and development with integrated ambr™ Reduced time to clinic – reduced time to market Strain generation reduced from six to four weeks

Cost efficiency

  • High yield protein production through class leading fermentation productivity, with potential for reduced cost of goods

Regulatory

  • Antibiotic-free cGMP large-scale manufacturing with high yield and versatility

Flexibility

  • Wide range of biotherapeutic proteins and accumulation routes: intracellular soluble, intracellular insoluble, and periplasmic secretionProven scalability
  • Suitable for large-scale manufacture – over 100 different therapeutic proteins produced at very high titers over the past decade

Rapid and scalable upstream process development with ambr® 250

High-throughput design and analysis tools ensure rapid, scalable upstream process development. Workflow is accelerated by automated screening for specificity and productivity using integrated ambr™ 250 technology. By implementing the ambr™250 technologies we have reduced strain generation from six to four weeks.